Planchard D, Smit E, Groen H, et al. Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E–mutant metastatic non-small cell lung cancer (NSCLC). ESMO 2017 Congress, abstract LBA51
Behandeling stadium II-III niet-kleincellig longcarcinoom gaat flink op de schop
apr 2024 | Immuuntherapie, Longoncologie